CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONSStock Option Grant Agreement • March 27th, 2024 • Cardiff Oncology, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 27th, 2024 Company IndustryCardiff Oncology, Inc., a Delaware corporation (the “Company”) does hereby grant to Tod Smeal (the “Optionee”), an option (the “Option”) that is NOT intended to qualify as an incentive stock option pursuant to Section 422(b) of the Internal Revenue Code, to purchase shares of the Company’s common stock (“Stock”) in the number and subject to terms and conditions of this Stock Option Grant Agreement (the “Grant Agreement”). The following are the general terms of the Option for shares of Stock (“Option Shares”) granted to Optionee by this Grant Agreement.
CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONSStock Option Grant Agreement • March 27th, 2024 • Cardiff Oncology, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 27th, 2024 Company IndustryCardiff Oncology, Inc., a Delaware corporation (the “Company”) does hereby grant to Rananand Arun Subramanian (the “Optionee”), an option (the “Option”) that is NOT intended to qualify as an incentive stock option pursuant to Section 422(b) of the Internal Revenue Code, to purchase shares of the Company’s common stock (“Stock”) in the number and subject to terms and conditions of this Stock Option Grant Agreement (the “Grant Agreement”). The following are the general terms of the Option for shares of Stock (“Option Shares”) granted to Optionee by this Grant Agreement.
CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONSStock Option Grant Agreement • March 27th, 2024 • Cardiff Oncology, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 27th, 2024 Company IndustryCardiff Oncology, Inc., a Delaware corporation (the “Company”) does hereby grant to Nancy Sherman (the “Optionee”), an option (the “Option”) that is NOT intended to qualify as an incentive stock option pursuant to Section 422(b) of the Internal Revenue Code, to purchase shares of the Company’s common stock (“Stock”) in the number and subject to terms and conditions of this Stock Option Grant Agreement (the “Grant Agreement”). The following are the general terms of the Option for shares of Stock (“Option Shares”) granted to Optionee by this Grant Agreement.
CARDIFF ONCOLOGY, INC. STOCK OPTION GRANT AGREEMENT FOR NONSTATUTORY STOCK OPTIONSStock Option Grant Agreement • March 27th, 2024 • Cardiff Oncology, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 27th, 2024 Company IndustryCardiff Oncology, Inc., a Delaware corporation (the “Company”) does hereby grant to James Levine (the “Optionee”), an option (the “Option”) that is NOT intended to qualify as an incentive stock option pursuant to Section 422(b) of the Internal Revenue Code, to purchase shares of the Company’s common stock (“Stock”) in the number and subject to terms and conditions of this Stock Option Grant Agreement (the “Grant Agreement”). The following are the general terms of the Option for shares of Stock (“Option Shares”) granted to Optionee by this Grant Agreement. Capitalized terms not defined herein shall have the meanings assigned to them in the Employment Agreement dated as of July 12, 2021 by and between the Optionee and the Company.